Argus Adjusts Price Target on Hologic to $95 From $89
Hologic (HOLX) has an average rating of outperform and price targets ranging from $70 to $95, according to analysts polled by Capital IQ.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
A Dive Into Hologic (HOLX) International Revenue Trends and Forecasts
Here Is What to Know Beyond Why Hologic, Inc. (HOLX) Is a Trending Stock
Hologic, Inc.'s (NASDAQ:HOLX) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 38.3x Hologic, Inc. (NASDAQ:HOLX) may be sending very bearish signals at the moment, given that almost half of all companies in the United States have P/E
Analysts Have Conflicting Sentiments on These Healthcare Companies: Community Health (CYH) and Hologic (HOLX)
Lumos Diagnostics Concludes Initial Phase of Development Deal With Hologic for Fetal Fibronectin Test; Shares Jump 6%
Lumos Diagnostics (ASX:LDX) concluded the initial stage of its development agreement, aimed at creating a novel fetal fibronectin (fFN) test for women's health company Hologic, according to a Monday f
Hologic Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Decoding Hologic Inc (HOLX): A Strategic SWOT Insight
Hologic Is Maintained at Overweight by JP Morgan
Hologic Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Hologic, Raises Price Target to $91
JP Morgan analyst Casey Woodring maintains Hologic (NASDAQ:HOLX) with a Overweight and raises the price target from $85 to $91.
Earnings Call Summary | Hologic(HOLX.US) Q2 2024 Earnings Conference
The following is a summary of the Hologic, Inc. (HOLX) Q2 2024 Earnings Call Transcript:Financial Performance:Hologic reported Q2 total revenue of $1.02 billion and non-GAAP earnings per share of $1.0
Hologic, Inc. (NASDAQ:HOLX) Q2 2024 Earnings Call Transcript
Research Alert: CFRA Maintains Hold View On Shares Of Hologic, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our 12-month target price by $5
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
UBS Adjusts Price Target on Hologic to $81 From $79, Maintains Neutral Rating
Hologic (HOLX) has an average outperform rating and a price target range of $70 to $95, according to analysts polled by Capital IQ. Price: 76.40, Change: +0.48, Percent Change: +0.64
Q2 2024 Hologic Inc Earnings Call
Needham: Reiterates the Hologic (HOLX.US) rating and adjusted from buy to buy, with a target price of $90.00.
Needham: Reiterates the Hologic (HOLX.US) rating and adjusted from buy to buy, with a target price of $90.00.
Needham Reiterates Buy on Hologic, Maintains $90 Price Target
Needham analyst Mike Matson reiterates Hologic (NASDAQ:HOLX) with a Buy and maintains $90 price target.
Hologic Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 15.38% Needham → $90 Reiterates Buy → Buy 04/10/2024 15.38% Needham → $90 Reiterates Buy → Buy
No Data